@noxopharm.bsky.social
Noxopharm announces the awarding of a TechVoucher grant for a joint project with UNSW Sydney, who will use the funding to explore how Noxopharm’s novel anti-inflammatory oligonucleotides could be used to reduce the inflammation caused by implants.
Read more here: www.noxopharm.com/pdf/8263eb2b...
Read more here: www.noxopharm.com/pdf/8263eb2b...
www.noxopharm.com
November 10, 2025 at 9:49 PM
Noxopharm announces the awarding of a TechVoucher grant for a joint project with UNSW Sydney, who will use the funding to explore how Noxopharm’s novel anti-inflammatory oligonucleotides could be used to reduce the inflammation caused by implants.
Read more here: www.noxopharm.com/pdf/8263eb2b...
Read more here: www.noxopharm.com/pdf/8263eb2b...
Lupus can have severe effects on people's lives and can be hard to diagnose - read more about the disease and the latest global research in the article below.
apnews.com/article/auto...
Disease of 1,000 faces shows how science is tackling immunity’s dark side
apnews.com/article/auto...
Disease of 1,000 faces shows how science is tackling immunity’s dark side
Disease of 1,000 faces shows how science is tackling immunity’s dark side
It's one of medicine's biggest mysteries — why sometimes our immune system attacks our own bodies. Autoimmune diseases affect as many as 50 million Americans and millions more worldwide.
apnews.com
November 9, 2025 at 11:32 PM
Lupus can have severe effects on people's lives and can be hard to diagnose - read more about the disease and the latest global research in the article below.
apnews.com/article/auto...
Disease of 1,000 faces shows how science is tackling immunity’s dark side
apnews.com/article/auto...
Disease of 1,000 faces shows how science is tackling immunity’s dark side
Noxopharm announces the start of the HERACLES clinical trial Part II, following successful single-dose testing. Multiple doses of ascending concentrations of SOF-SKN will continue safety testing at a more intensive level over a longer period of time. More here: www.noxopharm.com/pdf/1126c863...
www.noxopharm.com
November 4, 2025 at 10:15 PM
Noxopharm announces the start of the HERACLES clinical trial Part II, following successful single-dose testing. Multiple doses of ascending concentrations of SOF-SKN will continue safety testing at a more intensive level over a longer period of time. More here: www.noxopharm.com/pdf/1126c863...
The latest quarterly is now out, with news that Noxopharm has signed several collaboration agreements with Australian and international academic and research institutions.
Read more here: www.noxopharm.com/pdf/07c5e9d5...
Read more here: www.noxopharm.com/pdf/07c5e9d5...
www.noxopharm.com
October 29, 2025 at 11:26 PM
The latest quarterly is now out, with news that Noxopharm has signed several collaboration agreements with Australian and international academic and research institutions.
Read more here: www.noxopharm.com/pdf/07c5e9d5...
Read more here: www.noxopharm.com/pdf/07c5e9d5...
Great to see the Victorian Government supporting @hudsonresearch.bsky.social and Noxopharm's work taking our innovative SOF-SKN drug to a clinical trial and offering hope to people with lupus.
www.premier.vic.gov.au/world-first-...
www.premier.vic.gov.au/world-first-...
World-First RNA Trial A Breakthrough For Lupus Patients
Melbourne researchers have developed a new RNA drug designed to prevent the damaging effects of the debilitating autoimmune disease lupus, in a major breakthrough supported by the Allan Labor Governme...
www.premier.vic.gov.au
October 28, 2025 at 11:09 PM
Great to see the Victorian Government supporting @hudsonresearch.bsky.social and Noxopharm's work taking our innovative SOF-SKN drug to a clinical trial and offering hope to people with lupus.
www.premier.vic.gov.au/world-first-...
www.premier.vic.gov.au/world-first-...
Noxopharm has announced it has been granted its first US patent for the Sofra™ technology platform.
It relates to how Noxopharm’s innovative immune-modulatory oligonucleotides could harness the immune system for the treatment of certain cancers.
Read more here: www.noxopharm.com/pdf/96da7dc3...
It relates to how Noxopharm’s innovative immune-modulatory oligonucleotides could harness the immune system for the treatment of certain cancers.
Read more here: www.noxopharm.com/pdf/96da7dc3...
www.noxopharm.com
October 21, 2025 at 10:12 PM
Noxopharm has announced it has been granted its first US patent for the Sofra™ technology platform.
It relates to how Noxopharm’s innovative immune-modulatory oligonucleotides could harness the immune system for the treatment of certain cancers.
Read more here: www.noxopharm.com/pdf/96da7dc3...
It relates to how Noxopharm’s innovative immune-modulatory oligonucleotides could harness the immune system for the treatment of certain cancers.
Read more here: www.noxopharm.com/pdf/96da7dc3...
The immune system is centre stage once again as this year's Nobel Prize in Physiology or Medicine is awarded for groundbreaking discoveries concerning peripheral immune tolerance.
www.nobelprize.org/prizes/medic...
www.nobelprize.org/prizes/medic...
Nobel Prize in Physiology or Medicine 2025
The Nobel Prize in Physiology or Medicine 2025 was awarded jointly to Mary E. Brunkow, Frederick J. Ramsdell and Shimon Sakaguchi "for their discoveries concerning peripheral immune tolerance"
www.nobelprize.org
October 9, 2025 at 12:08 AM
The immune system is centre stage once again as this year's Nobel Prize in Physiology or Medicine is awarded for groundbreaking discoveries concerning peripheral immune tolerance.
www.nobelprize.org/prizes/medic...
www.nobelprize.org/prizes/medic...
Check out the company's latest media coverage on Stockhead.
Noxopharm has the 'burning fire' of inflammation squarely in its sights: stockhead.com.au/health/biocu...
Noxopharm has the 'burning fire' of inflammation squarely in its sights: stockhead.com.au/health/biocu...
Biocurious: Noxopharm has the 'burning fire' of inflammation squarely in its sights - Stockhead
After a strategy revamp Noxopharm is pursuing a clinical program targeting inflammation, notably the painful condition skin lupus.
stockhead.com.au
September 17, 2025 at 4:01 AM
Check out the company's latest media coverage on Stockhead.
Noxopharm has the 'burning fire' of inflammation squarely in its sights: stockhead.com.au/health/biocu...
Noxopharm has the 'burning fire' of inflammation squarely in its sights: stockhead.com.au/health/biocu...
Noxopharm announces the fourth and last single-dose cohort of SOF-SKN™, a novel drug candidate for autoimmune diseases, has been successfully completed in the HERACLES trial.
Read more here: www.noxopharm.com/pdf/e50f60a8...
Read more here: www.noxopharm.com/pdf/e50f60a8...
www.noxopharm.com
September 7, 2025 at 11:49 PM
Noxopharm announces the fourth and last single-dose cohort of SOF-SKN™, a novel drug candidate for autoimmune diseases, has been successfully completed in the HERACLES trial.
Read more here: www.noxopharm.com/pdf/e50f60a8...
Read more here: www.noxopharm.com/pdf/e50f60a8...
Noxopharm has released a new Sofra™ presentation that includes an overview of the technology platform, global autoimmune disease therapeutics and cutaneous lupus market info, SOF-SKN advantages, and numerous catalysts.
Read it here: www.noxopharm.com/pdf/a11601fa...
Read it here: www.noxopharm.com/pdf/a11601fa...
www.noxopharm.com
August 27, 2025 at 11:38 PM
Noxopharm has released a new Sofra™ presentation that includes an overview of the technology platform, global autoimmune disease therapeutics and cutaneous lupus market info, SOF-SKN advantages, and numerous catalysts.
Read it here: www.noxopharm.com/pdf/a11601fa...
Read it here: www.noxopharm.com/pdf/a11601fa...
Noxopharm announces the third dose cohort of SOF-SKN™, a novel drug candidate for autoimmune diseases, has been successfully completed in the HERACLES trial. The fourth cohort will now receive the highest dose approved for this trial.
Read more here: www.noxopharm.com/pdf/42f7ce25...
Read more here: www.noxopharm.com/pdf/42f7ce25...
www.noxopharm.com
August 24, 2025 at 11:48 PM
Noxopharm announces the third dose cohort of SOF-SKN™, a novel drug candidate for autoimmune diseases, has been successfully completed in the HERACLES trial. The fourth cohort will now receive the highest dose approved for this trial.
Read more here: www.noxopharm.com/pdf/42f7ce25...
Read more here: www.noxopharm.com/pdf/42f7ce25...
Noxopharm is very proud to have been nominated as a finalist in this year's Health Industry Hub awards, which celebrate change-makers across the industry.
Read more about all the categories and finalists here: www.healthindustryhub.com.au/health-indus...
Read more about all the categories and finalists here: www.healthindustryhub.com.au/health-indus...
August 12, 2025 at 12:48 AM
Noxopharm is very proud to have been nominated as a finalist in this year's Health Industry Hub awards, which celebrate change-makers across the industry.
Read more about all the categories and finalists here: www.healthindustryhub.com.au/health-indus...
Read more about all the categories and finalists here: www.healthindustryhub.com.au/health-indus...
Noxopharm announces the second dose cohort of SOF-SKN™, a novel drug candidate for autoimmune diseases, has been successfully completed in the HERACLES trial. It will now proceed to the third cohort of participants, who will receive a higher dose.
Read more here: www.noxopharm.com/pdf/51866b0a...
Read more here: www.noxopharm.com/pdf/51866b0a...
www.noxopharm.com
August 10, 2025 at 11:24 PM
Noxopharm announces the second dose cohort of SOF-SKN™, a novel drug candidate for autoimmune diseases, has been successfully completed in the HERACLES trial. It will now proceed to the third cohort of participants, who will receive a higher dose.
Read more here: www.noxopharm.com/pdf/51866b0a...
Read more here: www.noxopharm.com/pdf/51866b0a...
Noxopharm has announced initial results from US company Tezcat Biosciences testing assets from the Sofra™ technology platform.
Tezcat conducted a series of preclinical in vitro studies that resulted in highly promising outcomes.
Read more here: www.noxopharm.com/pdf/6d742ee9...
Tezcat conducted a series of preclinical in vitro studies that resulted in highly promising outcomes.
Read more here: www.noxopharm.com/pdf/6d742ee9...
www.noxopharm.com
August 4, 2025 at 11:26 PM
Noxopharm has announced initial results from US company Tezcat Biosciences testing assets from the Sofra™ technology platform.
Tezcat conducted a series of preclinical in vitro studies that resulted in highly promising outcomes.
Read more here: www.noxopharm.com/pdf/6d742ee9...
Tezcat conducted a series of preclinical in vitro studies that resulted in highly promising outcomes.
Read more here: www.noxopharm.com/pdf/6d742ee9...
Noxopharm has expanded the scope of its existing collaborations with three companies following the signing of Material Transfer Agreements several months previously. Read more news in the latest quarterly here: www.noxopharm.com/pdf/65a545cf...
www.noxopharm.com
July 29, 2025 at 10:55 PM
Noxopharm has expanded the scope of its existing collaborations with three companies following the signing of Material Transfer Agreements several months previously. Read more news in the latest quarterly here: www.noxopharm.com/pdf/65a545cf...
Noxopharm CEO Dr Gisela Mautner has featured as a panelist at Bio Connections Australia this week. The panel of accomplished female leaders discussed the role of women in the industry and how biotech companies can attract and retain more women in executive and scientific roles.
July 29, 2025 at 1:40 AM
Noxopharm CEO Dr Gisela Mautner has featured as a panelist at Bio Connections Australia this week. The panel of accomplished female leaders discussed the role of women in the industry and how biotech companies can attract and retain more women in executive and scientific roles.
Noxopharm announces the first dose cohort of SOF-SKN™, a novel drug candidate for autoimmune diseases, has been successfully completed in the HERACLES trial. It will now proceed to the second cohort of participants, who will receive a higher dose.
Read more here: www.noxopharm.com/pdf/8dbd34b1...
Read more here: www.noxopharm.com/pdf/8dbd34b1...
www.noxopharm.com
July 27, 2025 at 11:53 PM
Noxopharm announces the first dose cohort of SOF-SKN™, a novel drug candidate for autoimmune diseases, has been successfully completed in the HERACLES trial. It will now proceed to the second cohort of participants, who will receive a higher dose.
Read more here: www.noxopharm.com/pdf/8dbd34b1...
Read more here: www.noxopharm.com/pdf/8dbd34b1...
A major milestone reached with the first dose administered in the HERACLES trial for SOF-SKN™, a novel drug candidate for autoimmune diseases.
Noxopharm CEO Dr Gisela Mautner said: “We have taken our first Sofra drug candidate into the clinic at a rapid pace.”
www.noxopharm.com/pdf/e997b104...
Noxopharm CEO Dr Gisela Mautner said: “We have taken our first Sofra drug candidate into the clinic at a rapid pace.”
www.noxopharm.com/pdf/e997b104...
www.noxopharm.com
July 15, 2025 at 11:41 PM
A major milestone reached with the first dose administered in the HERACLES trial for SOF-SKN™, a novel drug candidate for autoimmune diseases.
Noxopharm CEO Dr Gisela Mautner said: “We have taken our first Sofra drug candidate into the clinic at a rapid pace.”
www.noxopharm.com/pdf/e997b104...
Noxopharm CEO Dr Gisela Mautner said: “We have taken our first Sofra drug candidate into the clinic at a rapid pace.”
www.noxopharm.com/pdf/e997b104...
Noxopharm has announced that recruitment activities are progressing rapidly for the HERACLES clinical trial. This involves activities such as advertising, as well as the identification, pre-screening and full screening of participants. Read more here: www.noxopharm.com/pdf/818fbb39...
www.noxopharm.com
June 25, 2025 at 12:19 AM
Noxopharm has announced that recruitment activities are progressing rapidly for the HERACLES clinical trial. This involves activities such as advertising, as well as the identification, pre-screening and full screening of participants. Read more here: www.noxopharm.com/pdf/818fbb39...
Noxopharm has announced positive data generated by an overseas company that has tested novel assets from the Sofra™ platform.
BioRay Pharmaceutical is a pioneer in China’s biopharmaceutical industry focusing on immune-mediated diseases.
Read more here: www.noxopharm.com/pdf/8b484f06...
BioRay Pharmaceutical is a pioneer in China’s biopharmaceutical industry focusing on immune-mediated diseases.
Read more here: www.noxopharm.com/pdf/8b484f06...
www.noxopharm.com
June 11, 2025 at 1:31 AM
Noxopharm has announced positive data generated by an overseas company that has tested novel assets from the Sofra™ platform.
BioRay Pharmaceutical is a pioneer in China’s biopharmaceutical industry focusing on immune-mediated diseases.
Read more here: www.noxopharm.com/pdf/8b484f06...
BioRay Pharmaceutical is a pioneer in China’s biopharmaceutical industry focusing on immune-mediated diseases.
Read more here: www.noxopharm.com/pdf/8b484f06...
Noxopharm has secured Human Research Ethics Committee approval for the HERACLES first-in-human clinical trial of SOF-SKN™, a novel drug candidate for inflammatory diseases. Work now begins on site initiation, logistics, and participant recruitment.
Read more here: www.noxopharm.com/pdf/558ce5d0...
Read more here: www.noxopharm.com/pdf/558ce5d0...
www.noxopharm.com
May 28, 2025 at 11:38 PM
Noxopharm has secured Human Research Ethics Committee approval for the HERACLES first-in-human clinical trial of SOF-SKN™, a novel drug candidate for inflammatory diseases. Work now begins on site initiation, logistics, and participant recruitment.
Read more here: www.noxopharm.com/pdf/558ce5d0...
Read more here: www.noxopharm.com/pdf/558ce5d0...
Noxopharm has presented clinically relevant SOF-SKN™ data at the Australian Rheumatology Association’s Annual Scientific Meeting, marking the company's first engagement at a specialist rheumatology event.
Read more here: www.noxopharm.com/pdf/31e0094f...
Read more here: www.noxopharm.com/pdf/31e0094f...
www.noxopharm.com
May 5, 2025 at 11:26 PM
Noxopharm has presented clinically relevant SOF-SKN™ data at the Australian Rheumatology Association’s Annual Scientific Meeting, marking the company's first engagement at a specialist rheumatology event.
Read more here: www.noxopharm.com/pdf/31e0094f...
Read more here: www.noxopharm.com/pdf/31e0094f...
Noxopharm has now applied for Human Research Ethics Committee approval for the HERACLES clinical trial.
CEO Dr Gisela Mautner said: “The preclinical testing phase has gone extremely well, and we have advanced our program expeditiously.”
Read more here: www.noxopharm.com/pdf/4adb03b0...
CEO Dr Gisela Mautner said: “The preclinical testing phase has gone extremely well, and we have advanced our program expeditiously.”
Read more here: www.noxopharm.com/pdf/4adb03b0...
www.noxopharm.com
May 1, 2025 at 11:24 PM
Noxopharm has now applied for Human Research Ethics Committee approval for the HERACLES clinical trial.
CEO Dr Gisela Mautner said: “The preclinical testing phase has gone extremely well, and we have advanced our program expeditiously.”
Read more here: www.noxopharm.com/pdf/4adb03b0...
CEO Dr Gisela Mautner said: “The preclinical testing phase has gone extremely well, and we have advanced our program expeditiously.”
Read more here: www.noxopharm.com/pdf/4adb03b0...
Noxopharm has signed a follow-on MTA with an international company to widen the scope of an ongoing project. CEO Dr Gisela Mautner said: “We continue to see external interest growing in our Sofra technology.”
Read more in the latest quarterly here: www.noxopharm.com/pdf/11c1c8db...
Read more in the latest quarterly here: www.noxopharm.com/pdf/11c1c8db...
www.noxopharm.com
April 29, 2025 at 11:22 PM
Noxopharm has signed a follow-on MTA with an international company to widen the scope of an ongoing project. CEO Dr Gisela Mautner said: “We continue to see external interest growing in our Sofra technology.”
Read more in the latest quarterly here: www.noxopharm.com/pdf/11c1c8db...
Read more in the latest quarterly here: www.noxopharm.com/pdf/11c1c8db...
Noxopharm CEO Dr Gisela Mautner said: “The accelerated pace with which we have progressed SOF-SKN reflects our determination to explore the potential of this innovative technology in a clinical setting as quickly as possible.”
April 14, 2025 at 10:54 PM
Noxopharm CEO Dr Gisela Mautner said: “The accelerated pace with which we have progressed SOF-SKN reflects our determination to explore the potential of this innovative technology in a clinical setting as quickly as possible.”